This past month, three new generic inhalers hit the market, and according to the GoodRx Index, patients are rapidly switching over to more affordable generics.
The GoodRx Index also featured the following trends in the month of February:
Flu season is raging on, and fills are elevated for Tamiflu and other antibiotics.
Actimmune is still the most expensive drug in America, but there have been some changes to the top 20 most expensive drug list.
Late this January, three popular brand-name inhalers went generic: Advair Diskus, Proair HFA, and Ventolin HFA. The new generic inhalers became available to the public in February, and according to the GoodRx Index, patients are quickly switching over to the more affordable generic alternatives.
Advair Diskus’ generic, fluticasone/salmeterol, is now available in pharmacies for around $150 per inhaler with a GoodRx coupon, which is about 50% cheaper than the brand inhaler. After its approval on January 30, fills for brand-name Advair plummeted as patients started to fill for the generic.
As of the last week of February, 0.10% of all prescriptions nationwide were for Advair, while 0.7% were for the generic. While fills for the generic have not yet surpassed fills for the brand, at this rate, it’s likely that fluticasone/salmeterol will account for the majority of fills by the end of March.
A similar trend can also be seen for Ventolin HFA. As of the last week of February, 0.43% of all prescription fills nationwide were for brand-name Ventolin, while 0.67% were for its generic, albuterol.
Albuterol, the generic version of Ventolin, is available in pharmacies for as little as $30 per inhaler. This is about 50% cheaper than brand-name Ventolin, which has an average cash price of around $74 per inhaler.
Just like Ventolin, Proair is an albuterol inhaler—and the generic is available for around $30 with a GoodRx discount.
During the last week of February, fill rates for Proair and albuterol were nearly identical—0.36% of all nationwide claims were for Proair compared to 0.33% for albuterol.
Are you taking any of these inhalers? If so, you might notice that your doctor or pharmacist has switched you over to the generic alternative. If you’re paying out of pocket, that’s good news for your wallet!
Flu season started late this year, and Americans are still feeling the effects. Not only are we seeing an increase in claims for the popular flu medication, Tamiflu, but fills for antibiotics are also on the rise. Specifically, fills for cefdinir and amoxicillin, antibiotics used for bacterial infections, are up 17% and 16% since January, respectively.
While this year’s flu season began with influenza A(H1N1) being the dominant flu strain, a more severe strain of the flu, influenza A(H3N2), is now accounting for more than half of all flu cases, and experts believe this to be the cause for our prolonged season. We aren’t out of the woods yet, so remember that it’s still not too late to get your flu shot.
Every month, GoodRx tracks the most popular outpatient drugs prescribed in the U.S., comparing total prescriptions written and filled for all forms of the medications. This analysis is based on a representative sample of prescriptions filled at U.S. pharmacies across the 50 states. The result is a top 10 list of the most prescribed drugs in the United States.
These were the 20 most expensive outpatient drugs in February based on list prices (the price set by the manufacturer) for a typical one-month prescription.
Actimmune – $52,322
Myalept – $46,328
Daraprim – $45,000
Cinryze – $44,141
Takhzyro – $44,140
Chenodal – $42,570
Juxtapid – $40,671
H.P. Acthar – $38,892
Tegsedi – $34,600
Ravicti – $33,572
Vitrakvi – $32,800
Firazyr – $32,468
Cuprimine – $31,426
Sovaldi – $28,000
Viekira Pak – $27,773
Viekira XR – $27,773
Orfadin – $27,247
Tibsovo – $26,115
Cerdelga – $26,000
Remodulin – $25,466
Since November, when we released our previous Top 20 list, things have changed, and not for the better.
Here’s what’s different:
On January 1, 2019 manufacturer Aegerion Pharmaceuticals increased the price of Myalept and Juxtapid by 9.95%, moving the drugs to number 2 and 7 on the list, respectively.
Horizon Pharma increased the price of Ravicti by 4.9% to a list price of $33,572, and it is now the 10th most expensive drug in the US.
United Therapeutics Corporation increased the price for Tyvaso by 4.9% on January 1, 2019. A monthly supply now costs $29,886, making Tyvaso the 14th most expensive drug in the U.S.
Harvoni and Zavesca’s generics both hit pharmacies, and now patients can access these drugs at a lower price.
Manufacturer Sanofi Genzyme increased the price of Cerdelga by 5% on January 15, 2019, bringing it to number 19 on this list.
Vitrakvi was approved on November 26, 2019, and at $546.67 per capsule, is now the 11th most expensive drug.
A new analysis from the GoodRx research team revealed that compared to where we were in 2017, more Americans are now uninsured, and those who are insured say their health costs are now higher.
GoodRx research showed just how much income affects health. Read our report here, and related coverage on the New York Times here.
Generics for hepatitis C drugs Harvoni and Epclusa hit pharmacies.
The FDA released a new warning about supplements falsely claiming to prevent and cure Alzheimer’s.
– – –
This data reflects overall U.S. prescriptions (not fills using GoodRx) and comes from several sources, including pharmacies and insurers, providing a representative sample of nationwide claims.
Don’t miss out on savings!